Publications

Bandini C; Pupuleku A; Spaccarotella E; Pellegrino E; Wang R; Vitale N; Duval C; Cantarella D; Rinaldi A; Provero P; Di Cunto F; Medico E; Bertoni F; Inghirami G; Piva R, 2018. IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell Lymphomas.  Cancers (Basel) 10.

Restelli V; Lupi M; Vagni M; Chilà R; Bertoni F; Damia G; Carrassa L, 2018. Combining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines.  Target Oncol 13(2):235-245

Spriano F; Chung EY; Panini N; Cascione L; Rinaldi A; Erba E; Stathis A; D'Incalci M; Bertoni F; Gatta R, 2018. Trabectedin is a novel chemotherapy agent for diffuse large B cell lymphoma.  Br J Haematol.

Chen J; Guccini I; Di Mitri D; Brina D; Revandkar A; Sarti M; Pasquini E; Alajati A; Pinton S; Losa M; Civenni G; Catapano CV; Sgrignani J; Cavalli A; D'Antuono R; Asara JM; Morandi A; Chiarugi P; Crotti S; Agostini M; Montopoli M; Masgras I; Rasola A; Garcia-Escudero R; Delaleu N; Rinaldi A; Bertoni F; Bono J; Carracedo A; Alimonti A, 2018. Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer.  Nat Genet 50(2):219-228

Tarantelli C; Gaudio E; Arribas AJ; Kwee I; Hillmann P; Rinaldi A; Cascione L; Spriano F; Bernasconi E; Guidetti F; Carrassa L; Pittau RB; Beaufils F; Ritschard R; Rageot D; Sele A; Dossena B; Rossi FM; Zucchetto A; Taborelli M; Gattei V; Rossi D; Stathis A; Stussi G; Broggini M; Wymann MP; Wicki A; Zucca E; Cmiljanovic V; Fabbro D; Bertoni F, 2018. PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy.  Clin Cancer Res 24(1):120-129

Sgrignani J; Chen J; Alimonti A; Cavalli A, 2018. How phosphorylation influences E1 subunit pyruvate dehydrogenase: A computational study.  Sci Rep 8(1):14683

Restelli V; Vagni M; Arribas AJ; Bertoni F; Damia G; Carrassa L, 2018. Inhibition of CHK1 and WEE1 as a new therapeutic approach in diffuse large B cell lymphomas with MYC deregulation.  Br J Haematol 181(1):129-133

Sgrignani J; Garofalo M; Matkovic M; Merulla J; Catapano CV; Cavalli A, 2018. Structural Biology of STAT3 and Its Implications for Anticancer Therapies Development.  Int J Mol Sci 19.

Bertoni F; Rossi D; Zucca E, 2018. Recent advances in understanding the biology of marginal zone lymphoma.  F1000Res 7:406

Conconi A; Zucca E; Margiotta-Casaluci G; Darling K; Hasse B; Battegay M; Staehelin C; Novak U; Schmid P; Scherrer A; Dirnhofer S; Kwee I; Nassi L; Cavalli F; Gaidano G; Bertoni F; Bernasconi E, 2018. Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals.  Hematol Oncol.

Condoluci A; Rossi D; Zucca E; Cavalli F, 2018. Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma.  Curr Oncol Rep 20(10):79

Nava Rodrigues D; Rescigno P; Liu D; Yuan W; Carreira S; Lambros MB; Seed G; Mateo J; Riisnaes R; Mullane S; Margolis C; Miao D; Miranda S; Dolling D; Clarke M; Bertan C; Crespo M; Boysen G; Ferreira A; Sharp A; Figueiredo I; Keliher D; Aldubayan S; Burke KP; Sumanasuriya S; Fontes MS; Bianchini D; Zafeiriou Z; Teixeira Mendes LS; Mouw K; Schweizer MT; Pritchard CC; Salipante S; Taplin ME; Beltran H; Rubin MA; Cieslik M; Robinson D; Heath E; Schultz N; Armenia J; Abida W; Scher H; Lord C; D'Andrea A; Sawyers CL; Chinnaiyan AM; Alimonti A; Nelson PS; Drake CG; Van Allen EM; de Bono JS, 2018. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.  J Clin Invest 128(10):4441-4453

Minotti G; Han H; Cattan V; Egorov A; Bertoni F, 2018. Pixantrone: novel mode of action and clinical readouts.  Expert Rev Hematol 11(7):587-596

Chen J; Guccini I; Di Mitri D; Brina D; Revandkar A; Sarti M; Pasquini E; Alajati A; Pinton S; Losa M; Civenni G; Catapano CV; Sgrignani J; Cavalli A; D'Antuono R; Asara JM; Morandi A; Chiarugi P; Crotti S; Agostini M; Montopoli M; Masgras I; Rasola A; Garcia-Escudero R; Delaleu N; Rinaldi A; Bertoni F; de Bono J; Carracedo A; Alimonti A, 2018. Publisher Correction: Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer.  Nat Genet 50(9):1343

Mensah AA; Cascione L; Gaudio E; Tarantelli C; Bomben R; Bernasconi E; Zito D; Lampis A; Hahne JC; Rinaldi A; Stathis A; Zucca E; Kwee I; Gattei V; Valeri N; Riveiro ME; Bertoni F, 2018. Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma.  Haematologica.

Civenni G; Carbone GM; Catapano CV, 2018. Overview of Genetically Engineered Mouse Models of Prostate Cancer and Their Applications in Drug Discovery.  Curr Protoc Pharmacol 81(1):e39

Calcinotto A; Spataro C; Zagato E; Di Mitri D; Gil V; Crespo M; De Bernardis G; Losa M; Mirenda M; Pasquini E; Rinaldi A; Sumanasuriya S; Lambros MB; Neeb A; Lucianò R; Bravi CA; Nava-Rodrigues D; Dolling D; Prayer-Galetti T; Ferreira A; Briganti A; Esposito A; Barry S; Yuan W; Sharp A; de Bono J; Alimonti A, 2018. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer.  Nature 559(7714):363-369

Pisignano G; Napoli S; Magistri M; Mapelli SN; Pastori C; Di Marco S; Civenni G; Albino D; Enriquez C; Allegrini S; Mitra A; D'Ambrosio G; Mello-Grand M; Chiorino G; Garcia-Escudero R; Varani G; Carbone GM; Catapano CV, 2017. A promoter-proximal transcript targeted by genetic polymorphism controls E-cadherin silencing in human cancers.  Nat Commun 8:15622

Genini D; Brambilla L; Laurini E; Merulla J; Civenni G; Pandit S; D'Antuono R; Perez L; Levy DE; Pricl S; Carbone GM; Catapano CV, 2017. Mitochondrial dysfunction induced by a SH2 domain-targeting STAT3 inhibitor leads to metabolic synthetic lethality in cancer cells.  Proc Natl Acad Sci U S A 114(25):E4924-E4933

Leoni C; Montagner S; Rinaldi A; Bertoni F; Polletti S; Balestrieri C; Monticelli S, 2017. Dnmt3a restrains mast cell inflammatory responses.  Proc Natl Acad Sci U S A 114(8):E1490-E1499

Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M, 2017. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.  Oncotarget 8(5):7598-7613

Arribas AJ; Bertoni F, 2017. Methylation patterns in marginal zone lymphoma.  Best Pract Res Clin Haematol 30(1-2):24-31

Akhmedov M; Kedaigle A; Chong RE; Montemanni R; Bertoni F; Fraenkel E; Kwee I, 2017. PCSF: An R-package for network-based interpretation of high-throughput data.  PLoS Comput Biol 13(7):e1005694

Bernasconi E; Gaudio E; Lejeune P; Tarantelli C; Cascione L; Kwee I; Spriano F; Rinaldi A; Mensah AA; Chung E; Stathis A; Siegel S; Schmees N; Ocker M; Zucca E; Haendler B; Bertoni F, 2017. Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma.  Br J Haematol 178(6):936-948

Bulian P; Bomben R; Bo MD; Zucchetto A; Rossi FM; Degan M; Pozzo F; Bittolo T; Bravin V; D'Agaro T; Cerri M; Chiarenza A; Chaffee KG; Condoluci A; D'Arena G; Spina M; Zaja F; Pozzato G; Di Raimondo F; Rossi D; Poeta GD; Gaidano G; Shanafelt TD; Gattei V, 2017. Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia.  Haematologica 102(11):e443-e446

Napoli S; Piccinelli V; Mapelli SN; Pisignano G; Catapano CV, 2017. Natural antisense transcripts drive a regulatory cascade controlling c-MYC transcription.  RNA Biol 14(12):1742-1755

Cascione L; Rinaldi A; Chiappella A; Kwee I; Ciccone G; Altenbuchinger M; Kohler C; Vitolo U; Inghirami G; Bertoni F, 2017. Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 study.  Br J Haematol.

Zabala-Letona A; Arruabarrena-Aristorena A; Martín-Martín N; Fernandez-Ruiz S; Sutherland JD; Clasquin M; Tomas-Cortazar J; Jimenez J; Torres I; Quang P; Ximenez-Embun P; Bago R; Ugalde-Olano A; Loizaga-Iriarte A; Lacasa-Viscasillas I; Unda M; Torrano V; Cabrera D; van Liempd SM; Cendon Y; Castro E; Murray S; Revandkar A; Alimonti A; Zhang Y; Barnett A; Lein G; Pirman D; Cortazar AR; Arreal L; Prudkin L; Astobiza I; Valcarcel-Jimenez L; Zuñiga-García P; Fernandez-Dominguez I; Piva M; Caro-Maldonado A; Sánchez-Mosquera P; Castillo-Martín M; Serra V; Beraza N; Gentilella A; Thomas G; Azkargorta M; Elortza F; Farràs R; Olmos D; Efeyan A; Anguita J; Muñoz J; Falcón-Pérez JM; Barrio R; Macarulla T; Mato JM; Martinez-Chantar ML; Cordon-Cardo C; Aransay AM; Marks K; Baselga J; Tabernero J; Nuciforo P; Manning BD; Marjon K; Carracedo A, 2017. mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer.  Nature 547(7661):109-113

Albino D; Civenni G; Dallavalle C; Roos M; Jahns H; Curti L; Rossi S; Pinton S; D'Ambrosio G; Sessa F; Hall J; Catapano CV; Carbone GM, 2016. Activation of the Lin28/let-7 Axis by Loss of ESE3/EHF Promotes a Tumorigenic and Stem-like Phenotype in Prostate Cancer.  Cancer Res 76(12):3629-43

Groner AC; Cato L; de Tribolet-Hardy J; Bernasocchi T; Janouskova H; Melchers D; Houtman R; Cato ACB; Tschopp P; Gu L; Corsinotti A; Zhong Q; Fankhauser C; Fritz C; Poyet C; Wagner U; Guo T; Aebersold R; Garraway LA; Wild PJ; Theurillat JP; Brown M, 2016. TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer.  Cancer Cell 29(6):846-858

Zucca E; Bertoni F, 2016. The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance.  Blood 127(17):2082-92

Delaleu N; Mydel P; Brun JG; Jonsson MV; Alimonti A; Jonsson R, 2016. Sjögren's syndrome patients with ectopic germinal centers present with a distinct salivary proteome.  Rheumatology (Oxford) 55(6):1127-37

Di Mitri D; Alimonti A, 2016. Non-Cell-Autonomous Regulation of Cellular Senescence in Cancer.  Trends Cell Biol 26(3):215-226

Bernasconi E; Gaudio E; Kwee I; Bertoni F, 2016. Assessment of the Antiproliferative Activity of a BET Bromodomain Inhibitor as Single Agent and in Combination in Non-Hodgkin Lymphoma Cell Lines.  Methods Mol Biol 1436:305-12

Civenni G; Longoni N; Costales P; Dallavalle C; García Inclán C; Albino D; Nuñez LE; Morís F; Carbone GM; Catapano CV, 2016. EC-70124, a Novel Glycosylated Indolocarbazole Multikinase Inhibitor, Reverts Tumorigenic and Stem Cell Properties in Prostate Cancer by Inhibiting STAT3 and NF-κB.  Mol Cancer Ther 15(5):806-18

Gaudio E; Tarantelli C; Kwee I; Barassi C; Bernasconi E; Rinaldi A; Ponzoni M; Cascione L; Targa A; Stathis A; Goodstal S; Zucca E; Bertoni F, 2016. Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas.  Ann Oncol 27(6):1123-8

Gomes AL; Teijeiro A; Burén S; Tummala KS; Yilmaz M; Waisman A; Theurillat JP; Perna C; Djouder N, 2016. Metabolic Inflammation-Associated IL-17A Causes Non-alcoholic Steatohepatitis and Hepatocellular Carcinoma.  Cancer Cell 30(1):161-175

Pizzi M; Boi M; Bertoni F; Inghirami G, 2016. Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells.  Leukemia 30(9):1805-15

Matic I; Revandkar A; Chen J; Bisio A; Dall'Acqua S; Cocetta V; Brun P; Mancino G; Milanese M; Mattei M; Montopoli M; Alimonti A, 2016. Identification of Salvia haenkei as gerosuppressant agent by using an integrated senescence-screening assay.  Aging (Albany NY) 8(12):3223-3240

Revandkar A; Perciato ML; Toso A; Alajati A; Chen J; Gerber H; Dimitrov M; Rinaldi A; Delaleu N; Pasquini E; D'Antuono R; Pinton S; Losa M; Gnetti L; Arribas A; Fraering P; Bertoni F; Nepveu A; Alimonti A, 2016. Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence.  Nat Commun 7:13719

Boi M; Todaro M; Vurchio V; Yang SN; Moon J; Kwee I; Rinaldi A; Pan H; Crescenzo R; Cheng M; Cerchietti L; Elemento O; Riveiro ME; Cvitkovic E; Bertoni F; Inghirami G, 2016. Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.  Oncotarget 7(48):79637-79653

Riveiro ME; Astorgues-Xerri L; Vazquez R; Frapolli R; Kwee I; Rinaldi A; Odore E; Rezai K; Bekradda M; Inghirami G; D'Incalci M; Noel K; Cvitkovic E; Raymond E; Bertoni F, 2016. OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.  Oncotarget 7(51):84675-84687

Rabi T; Catapano CV, 2016. Aphanin, a triterpenoid from Amoora rohituka inhibits K-Ras mutant activity and STAT3 in pancreatic carcinoma cells.  Tumour Biol 37(9):12455-12464

Gaudio E; Tarantelli C; Ponzoni M; Odore E; Rezai K; Bernasconi E; Cascione L; Rinaldi A; Stathis A; Riveiro E; Cvitkovic E; Zucca E; Bertoni F, 2016. Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.  Oncotarget 7(36):58142-58147

Albino D; Civenni G; Rossi S; Mitra A; Catapano CV; Carbone GM, 2016. The ETS factor ESE3/EHF represses IL-6 preventing STAT3 activation and expansion of the prostate cancer stem-like compartment.  Oncotarget 7(47):76756-76768

Bernasconi E; Gaudio E; Kwee I; Rinaldi A; Cascione L; Tarantelli C; Mensah AA; Stathis A; Zucca E; Vesci L; Giannini G; Bertoni F, 2015. The novel atypical retinoid ST5589 down-regulates Aurora Kinase A and has anti-tumour activity in lymphoma pre-clinical models.  Br J Haematol 171(3):378-86

Conconi A; Lobetti-Bodoni C; Montoto S; Lopez-Guillermo A; Coutinho R; Matthews J; Franceschetti S; Bertoni F; Moccia A; Rancoita PM; Gribben J; Cavalli F; Gaidano G; Lister TA; Montserrat E; Ghielmini M; Zucca E, 2015. Life expectancy of young adults with follicular lymphoma.  Ann Oncol 26(11):2317-22

Restelli V; Chilà R; Lupi M; Rinaldi A; Kwee I; Bertoni F; Damia G; Carrassa L, 2015. Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736.  Oncotarget 6(35):37229-40

Conconi A; Franceschetti S; Aprile von Hohenstaufen K; Margiotta-Casaluci G; Stathis A; Moccia AA; Bertoni F; Ramponi A; Mazzucchelli L; Cavalli F; Gaidano G; Zucca E, 2015. Histologic transformation in marginal zone lymphomas†.  Ann Oncol 26(11):2329-35

Publication list retrieved from NCBI using ImpactPubs

.

NOTE: this list was automatically generated by PubMed using the search string ‘(Bertoni F OR Catapano CV OR Catapano C OR Alimonti A OR Carbone GM OR Theurillat JP OR Rossi D) AND (IOSI[AD] OR IOR[AD]) “last 3 years”[DP]’